Overview

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the time to progression (TTP) in patients with advanced HCC treated with Icaritin .
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Shenogen Biomedical Co., Ltd
Collaborators:
307 Hospital of PLA
Chinese Academy of Medical Sciences
NanJing PLA 81 Hospital
Qingdao University